Taimei Medical Technology reported unaudited interim results for the six months ended 30 June 2026, highlighting solid top-line expansion and margin improvement but a deeper statutory loss.

Revenue and Profitability • Revenue rose 8.00% year on year to RMB 263.64 million (USD ≈ 36.3 million), driven mainly by the AI Clinical Development Platform segment. • Gross profit climbed 17.50% to RMB 117.75 million, lifting the gross margin to 44.7% (1H25: 41.0%). • Operating loss widened 28.00% to RMB 62.37 million, while loss for the period increased 64.30% to RMB 48.16 million. Basic and diluted loss per share stood at RMB 0.08 (1H25: RMB 0.04). • On a non-IFRS basis, adjusted net loss narrowed 7.70% to RMB 30.91 million, and adjusted EBITDA loss decreased sharply to RMB 3.42 million (1H25: loss of RMB 20.71 million), reflecting improving operating leverage.

Segment Performance • AI Clinical Development Platforms generated RMB 158.78 million in revenue, up 22.20% year on year and representing 60.2% of group total. Segment gross margin reached 63.6%. • AI-enabled CRO services recorded revenue of RMB 104.86 million, down 8.30%, as Taimei Medical Technology continued to scale down lower-margin contracts; nevertheless, segment gross margin improved to 15.9%.

Order Intake • New contract value totalled RMB 363.50 million, an increase of 14.9%. – AI Clinical Development Platform contracts rose 46.9% to RMB 266.10 million, including RMB 122.80 million from the Wiz.AI platform (+67.4%). – AI-enabled CRO contracts declined 27.9% to RMB 97.40 million following the strategic business mix adjustment.

Cash Position and Balance Sheet • Cash and cash equivalents stood at RMB 477.32 million, supplemented by RMB 433.68 million in short-term bank deposits and RMB 136.25 million in short-term treasury investments. • Net current assets were RMB 1.06 billion; the current ratio was 4.39. • Total borrowings amounted to RMB 75.49 million, giving a gearing ratio of 23.2%. The group reported no material pledges, contingent liabilities or off-balance-sheet commitments.

Capital Management • During June 2026 the company repurchased 1.14 million H shares for HK$6.54 million, holding them as treasury shares for potential future use. • No interim dividend was declared.

Strategic Priorities Management plans to: 1. Continue R&D investment in the AI Clinical Development Platform, emphasising functional upgrades of the Wiz.AI platform. 2. Advance the restructuring of the AI-enabled CRO business to enhance profitability through deeper AI integration. 3. Expand international collaborations in Europe, the United States, South Korea, Australia and India. 4. Progress its Innovative Drug Pipeline Equity Fund, aiming to complete the first asset investment in 3Q26.

The company reported no significant post-period events other than continued share repurchases and H-share purchases by its share award scheme trustee.